Cipla Assessed $15.5 Million In Interest On Indian Drug Overcharge Fine
This article was originally published in PharmAsia News
India's drug-price regulator dunned Cipla an additional $15.5 million in interest stemming from an earlier charge of overpricing its drugs. The company said the National Pharmaceutical Pricing Authority assessed the interest for April 2007, through January, 2008, on a previous assessment of $186.3 million for overcharges. Among the drugs cited were the firm's ciprofloxacin, norfloxacin, salbutamol and theophyline drugs. (Click here for more
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.